A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
about
Targeting mTOR in Pancreatic Ductal AdenocarcinomaThe mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsGenomic alterations in pancreatic cancer and their relevance to therapyPancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinomaThe role of 1,25-dyhydroxyvitamin D3 in mouse liver ischemia reperfusion injury: regulation of autophagy through activation of MEK/ERK signaling and PTEN/PI3K/Akt/mTORC1 signaling.Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer.Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic cancer.The role of hypoxia in pancreatic cancer: a potential therapeutic target?ALDH1A3 correlates with luminal phenotype in prostate cancer.In vivo functional dissection of a context-dependent role for Hif1α in pancreatic tumorigenesis.BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells.Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma.Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells.MTOR inhibitor-based combination therapies for pancreatic cancer.Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-initiating Cells from Lung Adenocarcinoma.Characterization of human gastric adenocarcinoma cell lines established from peritoneal ascites.
P2860
Q26747291-942BFF22-D04C-4A51-9C37-DBF76E0A2528Q26751155-2627794B-BCD0-41DF-B8DC-8C07286F370BQ26781443-7048BB39-F909-42CA-A08B-0275BDCC2EDAQ36383994-E28F3A55-C215-40A9-8EC0-C2AF8F9850CAQ36516685-D6169740-46EA-47AA-AA37-FDF69879B58AQ36544797-6F269394-BF99-4FFB-AD00-90E66438FF79Q38631037-5A518974-2BC7-4D61-B639-E03A15CE80BEQ38631404-B239A61A-06B7-4F25-BDDD-DFFF80040AABQ38690835-129E0029-26EF-4EB0-9468-CC30FAE40391Q39678707-43D1A21E-A569-43CD-BB26-5DF938D5F9E3Q41280277-DDD8CDAB-50D1-4F0D-9ED7-35C8F2667CBEQ41781449-AA4D1EE8-4884-4CCB-BAC2-0DEC48E1D2B0Q42729081-000F6F60-2147-4F90-9973-1429DF6D1AECQ47230585-45D3A60C-3498-4145-B62F-599CF0DBB3DAQ47754576-4D5A31A3-9CAF-4C48-9DAB-3841B2B90EA9Q49560871-AE9BA977-EF95-4856-AEFA-1B63BE9244FDQ52714520-4EA849AD-710B-4AE5-B851-1DDFF0C34FFCQ55066691-CCFEBB7C-1D57-4BEA-85BA-AE0EC372C09E
P2860
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@en
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@nl
type
label
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@en
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@nl
prefLabel
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@en
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@nl
P2093
P2860
P50
P1433
P1476
A subset of metastatic pancrea ...... d hyperactive mTOR signalling.
@en
P2093
Andrea Tannapfel
Carsten Jäger
Chengjia Qian
Christoph W Michalski
Ivonne Regel
Jens T Siveke
Johannes Beckers
Jörg Kleeff
Nora Behler
P2860
P304
P356
10.1136/GUTJNL-2014-307616
P407
P577
2015-01-19T00:00:00Z